Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented by Drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by Brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by Geography.

Market Snapshot

GLP 1Asia pacific snapshot
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • The GLP-1 drugs are also known as “incretin mimetics,” a hormone that stimulates insulin secretion in response to meals.
  • GLP-1s are considered an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
  • Patients with type-2 diabetes have diminished insulin release in response to meals, and it is speculated that they may have defects in the release or action of their incretin hormones.
  • Diabetes prevalence has increased rapidly in recent decades. It is estimated that in 2007, more than 100 million Asians were living with diabetes. Concurrently with the rise in the diabetic population, obesity is also rising sharply because of economic development, increasing sedentary lifestyles, and nutrition transition. 
  • Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia, i.e., China and Japan. 

Scope of the Report

The Market is Segmented by Drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by Brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by Geography.

 

By Drug Exenatide Byetta
Bydureon
Liraglutide Victoza
Lixisenatide Lyxumia
Dulaglutide Trulicity
By Geography Asia-Pacific

 

Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

Key Market Trends

Ever Increasing Prevalence of Diabetes

  • The Asia-Pacific region suffers from a high burden of diabetes, and its adverse health and economic consequences.
  • The disease is not only viewed as a serious threat, just from a public health perspective, but also from a development perspective.
  • With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in the low- and middle-income countries of the region. It is one of the most common chronic diseases in China and India. 
  • China tops the global list of countries for the total number of people with diabetes, followed by India. The number of people with diabetes in Japan has also increased significantly.
  • According to the IDF in 2013, it is estimated that Japan occupied the 10th position in the IDF list, with 7.2 million people with diabetes. 
  • WHO projects that diabetes is likely to be the seventh leading cause of death by 2030. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years.
  • The growing prevalence of diabetes is the primary driver for the Asia-Pacific diabetes care market. Additionally, raising awareness regarding diabetes care, the ever-increasing prevalence of obesity, and technological advancements are further driving the market.
Picture1

Japan is Dominating the GLP-1 Market in the Asia-Pacific Region

  • Japan holds the highest share in the Asia-Pacific GLP-1 agonist market, followed by China. GLP-1 receptor agonists have effective glucose-lowering efficacies and remarkable weight-loss effects, and are beneficial for diabetes treatment, especially for patients with overweight/obesity.
  • In Asia-Pacific, the revenue generated by the GLP-1 market was USD 384.04 million in 2017, and the market is expected to grow steadily during the forecast period, at a considerable rate of 15.93%. The growth of the market can be attributed to the fact that the type-2 diabetic population is on the rise and is expected to see further increase in the future, due to the lifestyle choices of individuals.
  • By brand, Victoza occupies the significant market share, at 62.07%, and it is expected to witness a growth rate of 11.49% during the forecast period. Trulicity held 26.24%, as of 2017.
  • Trulicity has a growth rate of 25.48% and is expected to reach almost the same overall market value as of Victoza, by 2024.
GLP1 Japan

Competitive Landscape

  • The Asia-Pacific GLP-1 market is consolidated, with four major manufacturers holding a presence in the region.  
  • Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Sajjala Bio, Hyderabad, India, recently announced developments in a liraglutide biosimilar, and the company is aiming to launch the product by the end of 2019.  

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET INDICATORS

    1. 5.1 Type-1 Diabetes Population (2012-2024)

    2. 5.2 Type-2 Diabetes Population (2012-2024)

  6. 6. MARKET SEGMENTATION

    1. 6.1 By Drug

      1. 6.1.1 Exenatide

        1. 6.1.1.1 Byetta (Value and Volume, 2012-2024)

        2. 6.1.1.2 Bydureon (Value and Volume, 2012-2024)

      2. 6.1.2 Liraglutide

        1. 6.1.2.1 Victoza (Value and Volume, 2012-2024)

      3. 6.1.3 Lixisenatide

        1. 6.1.3.1 Lyxumia (Value and Volume, 2012-2024)

      4. 6.1.4 Dulaglutide

        1. 6.1.4.1 Trulicity (Value and Volume, 2012-2024)

    2. 6.2 Geography

      1. 6.2.1 Asia-Pacific

        1. 6.2.1.1 Japan (Value and Volume, 2012-2024)

          1. 6.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        2. 6.2.1.2 China (Value and Volume, 2012-2024)

          1. 6.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        3. 6.2.1.3 Australia (Value and Volume, 2012-2024)

          1. 6.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        4. 6.2.1.4 India (Value and Volume, 2012-2024)

          1. 6.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        5. 6.2.1.5 South Korea (Value and Volume, 2012-2024)

          1. 6.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        6. 6.2.1.6 Malaysia (Value and Volume, 2012-2024)

          1. 6.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        7. 6.2.1.7 Indonesia (Value and Volume, 2012-2024)

          1. 6.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        8. 6.2.1.8 Thailand (Value and Volume, 2012-2024)

          1. 6.2.1.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        9. 6.2.1.9 Philippines (Value and Volume, 2012-2024)

          1. 6.2.1.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        10. 6.2.1.10 Vietnam (Value and Volume, 2012-2024)

          1. 6.2.1.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

        11. 6.2.1.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)

          1. 6.2.1.11.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

          2. 6.2.1.11.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Astra Zeneca

    2. *List Not Exhaustive
    3. 7.2 MARKET SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Astra Zeneca

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Glucagon-like Peptide-1 Agonists Market market is studied from 2018 - 2026.

The Asia-Pacific Glucagon-like Peptide-1 Agonists Market is growing at a CAGR of 0% over the next 5 years.

Novo Nordisk, AstraZeneca, Eli Lilly and Company, Sanofi are the major companies operating in Asia-Pacific Glucagon-like Peptide-1 Agonists Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!